For research use only. Not for use in humans.

Ofatumumab (Anti-CD20)

Synonyms: Ms4a1, B1

Ofatumumab (Anti-CD20) is a fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. MW: 145.94 kD.

Ofatumumab (Anti-CD20)

Quality Control

Batch: A297101 Purity: 99% Protein concentration: 14.4mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Ofatumumab (Anti-CD20) is a fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. MW: 145.94 kD.
References

Product Details

CAS No. 679818-59-8
Molecular Weight 145.94
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06688331 RECRUITING Presymptomatic Diabetes Type 1 (Stage 1); Diabetes Mellitus, Type I; Diabetes Mellitus, Type 1 PolTREG S.A. 2025-03-12 PHASE2
NCT06824701 ACTIVE_NOT_RECRUITING Drug: Zanubrutinib|Drug: Rituximab|Drug: Obinutuzumab Relapsed or Refractory B-cell Non-Hodgkin Lymphoma University of Utah 2025-09-12 PHASE1
NCT07189325 RECRUITING Drug: Platform therapies (Dimethyl Fumarate, Teriflunomide, Relapsing-Remitting Multiple Sclerosis (RRMS); Anti-CD20 Therapy University Hospital, Montpellier 2026-06-15 PHASE3
NCT06149286 RECRUITING Drug: Odronextamab|Drug: Lenalidomide|Drug: Rituximab Relapsed/Refractory Follicular Lymphoma; Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) Regeneron Pharmaceuticals 2023-12-28 PHASE3
NCT07480863 ACTIVE_NOT_RECRUITING Drug: Orelabrutinib|Drug: Zuberitamab|Drug: Cyclophosphamide Marginal Zone Lymphoma(MZL) Cancer Institute and Hospital, Chinese Academy of Medical Sciences 2025-10-01 PHASE2
NCT06943872 RECRUITING Drug: Sonrotoclax|Drug: Obinutuzumab|Drug: Rituximab|Drug: V Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma BeOne Medicines 2025-06-11 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-07-17)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.